Liao Yulin, Asakura Masanori, Takashima Seiji, Ogai Akiko, Asano Yoshihiro, Asanuma Hiroshi, Minamino Tetsuo, Tomoike Hitonobu, Hori Masatsugu, Kitakaze Masafumi
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0781, Japan.
Cardiovasc Res. 2005 Mar 1;65(4):879-88. doi: 10.1016/j.cardiores.2004.11.006.
The effects of long-acting calcium channel blockers (CCBs) on pressure overload-induced cardiac remodeling are seldom studied in animals. We evaluated the effects of benidipine, a long-acting CCB, on cardiac remodeling.
Rat neonatal cardiac myocytes were used to examine the influence of benidipine on protein synthesis. Cardiac remodeling was induced in C57 B6/J mice by transverse aortic constriction (TAC). Then the effects of benidipine (10 mg/kg/d) were assessed on myocardial hypertrophy and heart failure, cardiac histology, and gene expression.
Benidipine significantly inhibited protein synthesis by cardiac myocytes stimulated with phenylephrine (PE), and this effect was partially abolished by cotreatment with a nitric oxide synthase (NOS) inhibitor [N(G)-nitro-l-arginine methylester (l-NAME)]. Four weeks after the onset of pressure overload, benidipine therapy potently inhibited cardiac hypertrophy and prevented heart failure. The heart to body weight ratio was 6.89+/-0.48 mg/g in treated mice vs. 8.76+/-0.33 mg/g in untreated mice (P<0.01), and the lung to body weight ratio was 7.39+/-0.93 mg/g vs. 10.53+/-0.99 mg/g, respectively (P<0.05). Left ventricular fractional shortening (LVFS) was improved on echocardiography. Plasma NO levels were increased, while B type natriuretic peptide, protein inhibitor of neuronal NOS, and procollagen IV alpha were down-regulated in benidipine-treated mice.
These results indicate that benidipine inhibits cardiac remodeling due to pressure overload at least partly by acting on the nitric oxide signaling pathway.
长效钙通道阻滞剂(CCB)对压力超负荷诱导的心脏重塑的影响在动物中很少被研究。我们评估了长效CCB贝尼地平对心脏重塑的影响。
使用大鼠新生心肌细胞来检测贝尼地平对蛋白质合成的影响。通过横向主动脉缩窄(TAC)在C57 B6/J小鼠中诱导心脏重塑。然后评估贝尼地平(10毫克/千克/天)对心肌肥大、心力衰竭、心脏组织学和基因表达的影响。
贝尼地平显著抑制去甲肾上腺素(PE)刺激的心肌细胞的蛋白质合成,并且一氧化氮合酶(NOS)抑制剂[N(G)-硝基-L-精氨酸甲酯(L-NAME)]共同处理可部分消除这种作用。压力超负荷开始四周后,贝尼地平治疗有效抑制心肌肥大并预防心力衰竭。治疗组小鼠的心脏与体重比为6.89±0.48毫克/克,未治疗组小鼠为8.76±0.33毫克/克(P<0.01),肺与体重比分别为7.39±0.93毫克/克和10.53±0.99毫克/克(P<0.05)。超声心动图显示左心室缩短分数(LVFS)得到改善。贝尼地平治疗的小鼠血浆NO水平升高,而B型利钠肽、神经元NOS蛋白抑制剂和胶原蛋白IVα下调。
这些结果表明,贝尼地平至少部分通过作用于一氧化氮信号通路抑制压力超负荷引起的心脏重塑。